Posted by Michael Wonder on 05 Jan 2022
U.S. FDA approves Immix Biopharma rare paediatric disease designation for IMX-110 as a treatment for life-threatening paediatric cancer
3 January 2021 - Immix Biopharma announced today that the U.S. FDA has granted rare paediatric disease designation for IMX-110 for the treatment of a life-threatening form of paediatric cancer in children, rhabdomyosarcoma.
IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial.
